sorafenib has been researched along with Lymph Node Metastasis in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (21.05) | 29.6817 |
| 2010's | 22 (57.89) | 24.3611 |
| 2020's | 8 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W; Wang, H; Zhang, D | 1 |
| Akiyama, S; Fujino, Y; Furutani, A; Kajimoto, K; Mohri, K; Murata, K; Otsubo, D; Sawa, H; Suzuki, S; Tanaka, M; Tominaga, M; Yamagishi, T; Yamane, H; Yoshida, T | 1 |
| Akhanlı, P; Bayır, Ö; Çakal, E; Düğer, H; Kertmen, H; Kızılgül, M; Korkmaz, MH; Saylam, G; Sencar, ME; Uçan, B; Yazılıtaş, D; Yılmazer, D | 1 |
| Cai, ZS; Chang, CW; Chen, MJ; Tang, TY | 1 |
| Nakamura, T; Sakamoto, K; Takada, Y; Tamura, K; Tohyama, T; Wakisaka, H; Watanabe, J | 1 |
| Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L | 1 |
| Ahn, DH; Bae, K; Han, HJ; Kim, JH; Moon, JS; Yoon, KA | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y | 1 |
| Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W | 1 |
| Kim, DY; Kim, YJ; Lee, SJ; Lim, HY; Lim, TS; Park, JW; Ryoo, BY; Yoo, C; Yu, SJ | 1 |
| Chen, X; Guo, J; Hu, X; Liu, L; Wang, H; Yao, J; Zheng, W; Zhu, Y | 1 |
| Fukuda, H; Iizuka, J; Ishida, H; Ishihara, H; Kobayashi, H; Kondo, T; Okumi, M; Takagi, T; Tanabe, K; Yoshida, K | 1 |
| Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R | 1 |
| Jiang, W; Zeng, ZC | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Yoo, BC | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
| Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B | 1 |
| Fountas, A; Giotaki, Z; Kalogeropoulos, CD; Tigas, S; Tsatsoulis, A | 1 |
| Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawasaki, J; Maehara, Y; Motomura, T; Nagatsu, A; Soejima, Y; Uchiyama, H; Yoshizumi, T | 1 |
| Ansari, J; Bhatt, RI; Chaudhri, S; Fatima, A; James, ND; Wallace, M | 1 |
| Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
| Frieling, T; Heise, J; Wassilew, SW | 1 |
| Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM | 1 |
| Pappo, A; Paulino, AC | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Chang, JW; Chang, NJ; Chuang, CK; Hou, MM; Hsieh, JJ; Hsu, T; Huang, HY; Wang, HM | 1 |
| Dralle, H; Machens, A | 1 |
| Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
| Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
| Aguillo Gutiérrez, E; Altemir Trallero, J; Cabrejas Gómez, Mdel C; Lázaro Sierra, J; Ocón Bretón, J | 1 |
| Escobar-Jiménez, F; García-Martín, A; López-Ibarra Lozano, PJ; Triviño-Ibáñez, EM | 1 |
| Flaherty, KT; Heitjan, DF; Kang, HC; Keefe, SM; O'Dwyer, PJ; Rosen, MA; Siegelman, ES; Tan, KS | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W | 1 |
| Hersey, P; Hong, A; Moncrieff, M; Shannon, K; Thompson, J | 1 |
| Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
1 review(s) available for sorafenib and Lymph Node Metastasis
| Article | Year |
|---|---|
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combinations; End Stage Liver Disease; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pharyngeal Neoplasms; Pharynx; Positron Emission Tomography Computed Tomography; Sorafenib; Tegafur; Treatment Outcome | 2020 |
4 trial(s) available for sorafenib and Lymph Node Metastasis
| Article | Year |
|---|---|
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2013 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Biomarkers, Tumor; Canada; Cell Proliferation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
33 other study(ies) available for sorafenib and Lymph Node Metastasis
| Article | Year |
|---|---|
[Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lymphatic Metastasis; Microsatellite Instability; RNA, Long Noncoding; Sorafenib | 2022 |
[Long-Term Survival of a Patient with Hepatocellular Carcinoma after Surgical Resection of Metachronous Hilar Lymph Node Metastases].
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Neoplasms; Lung; Lymph Nodes; Lymphatic Metastasis; Sorafenib | 2022 |
Metastatic diffuse follicular variant papillary thyroid cancer without cervical lymph node metastasis presenting with symptoms related to hypopituitarism.
Topics: Aged; Humans; Hypopituitarism; Iodine Radioisotopes; Lymphatic Metastasis; Male; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy | 2023 |
Duodenum perforated after combination with sorafenib and radiotherapy for retroperitoneal lymph node metastasis of hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Duodenum; Humans; Intestinal Perforation; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Radiotherapy; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Tomography, X-Ray Computed | 2020 |
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib | 2020 |
Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Circulating Tumor DNA; Dog Diseases; Dogs; Female; Lymphatic Metastasis; Mutation; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome; Urethral Neoplasms | 2021 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A | 2018 |
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2019 |
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Molecular Targeted Therapy; Neutrophils; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate | 2019 |
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib | 2020 |
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Retrospective Studies; Sorafenib; Survival Rate | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms | 2014 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Prospective Studies; Risk Factors; Sorafenib; Survival Analysis; Terminology as Topic | 2015 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Sorafenib; Thrombosis; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Choroidal metastasis from papillary thyroid cancer: An unusual feature of a common disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Choroid Neoplasms; Female; Goiter, Nodular; Humans; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy | 2017 |
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Liver Transplantation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphatic Metastasis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer | 2009 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms | 2010 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free Survival; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Translocation, Genetic; Treatment Outcome; Young Adult | 2010 |
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Clinical Trials, Phase II as Topic; Disease-Free Survival; Humans; Lymph Node Excision; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2010 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
[Long-standing differentiated thyroid carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillary; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Diagnostic Errors; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Niacinamide; Palliative Care; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Tuberculosis, Miliary | 2012 |
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms | 2013 |
Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Lower Extremity; Lymphatic Metastasis; Lymphedema; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |